SRRK
Scholar Rock Holding Corporation
Biotechnology · Healthcare · United States
43.90
close · 2026-10-30
value
90
cheaper than peers90
quality
8
stronger fundamentals8
ranked against
Biotechnology (pre-revenue)
value
quality
109 peerswide variation
Value inputs
| measure | company | vs peers |
| earnings yield, 2 years ago | -4.5% | 90 |
| earnings yield, 3 years ago | -5.1% | 88 |
| cash flow yield, 2 years ago | -2.7% | 83 |
| earnings yield, 1 year ago | -5.6% | 82 |
| earnings yield, latest year | -7.5% | 81 |
| cash flow yield, latest year | -5.6% | 80 |
| cash flow yield, 1 year ago | -3.8% | 80 |
| cash flow yield, 3 years ago | -2.5% | 80 |
| price to book | 21.03× | 6 |
9 of 12 measures available
Quality inputs
| measure | company | vs peers |
| operating margin | 0.0% | 50 |
| return on equity | -167.8% | 15 |
| debt to equity | 80.3% | 11 |
3 of 4 measures available
Facts
| market cap | $5B |
| free cash flow | -$153.9M |
| employees | 289 |
| first trade | 2018-05-25 |
| next earnings | 2026-11-10 |
| fundamentals updated | 2026-08-10 |
Annual history
| measure | 2025 | 2024 | 2023 | 2022 |
| diluted eps | -3.29 | -2.47 | -1.99 | -2.26 |
| free cash flow | -$300.6M | -$201.0M | -$145.3M | -$133.8M |
| net income | -$377.9M | -$246.3M | -$165.8M | -$134.5M |
| revenue | $0 | $0 | $0 | $33.2M |